Tremor Reduction in Parkinson's Disease

First-Line Pharmacologic Treatment

The American Academy of Neurology recommends starting with levodopa/carbidopa as initial therapy for tremor and other motor symptoms in newly diagnosed PD patients, as it provides superior efficacy compared to other agents 1
Levodopa should be administered at least 30 minutes before meals to optimize absorption, since dietary proteins compete with levodopa for gut transport and reduce its effectiveness 1
The American Academy of Neurology suggests that levodopa produces mean tremor improvement of 30-50% on the UPDRS rest tremor subscale 1

Deep Brain Stimulation (DBS) is the most well-established advanced therapy for medication-resistant tremor, offering long-term efficacy, reversibility, and effectiveness for other motor symptoms and fluctuations 1
Target either the subthalamic nucleus (STN) or globus pallidus internus (GPi) for motor symptom control 1
Choose STN DBS when medication reduction is a primary goal 1
Select GPi DBS if there are significant concerns about cognitive decline or depression risk 1
MRgFUS thalamotomy is a promising incisionless alternative with lower complication rates (4.4%) compared to DBS (21.1%), though it is not suitable for bilateral treatment 2
MRgFUS produces sustained tremor improvement of 56% at 2-4 years with stable maintenance of benefits 3, 4

The American Academy of Neurology advises against using beta-blockers (propranolol) as primary treatment for PD tremor, as these are indicated for essential tremor, not parkinsonian tremor 2
Avoid high-protein meals near levodopa dosing times, as protein competes with levodopa absorption and reduces efficacy 1
Do not delay advanced therapies (DBS or MRgFUS) in patients with medication-resistant disabling tremor, as quality of life significantly improves with these interventions 3
Monitor for side effects that may worsen with combination therapy, including dyskinesias (which may require levodopa dose reduction) and cognitive effects from anticholinergics 1